◾️【HNCSM】6/25 JUNE BRIDE.FES 開宴の日
お品書くほどじゃないのですが明日の頒布予定です
無配はB6、既刊はA5です！

Announcing the Annual Indian Head and Neck Oncology National meeting - FHNO 2024. We promise an exciting scientific meeting with high quality deliberations on all aspects of HN cancers. Come and join us. Early bird registrations end on 30th April #hncsm #FHNO2024

Staying comfortably on the H&N side of skull base with a SNUC #NASBS2023 #hncsm

Another example of the importance of the sequence of IO with respect to chemoradiation.

Superior LR control and PFS when pen to given sequentially after CRT in locally advanced head neck cancer.

#ESMO23 #hncsm

Delighted that the North Glasgow H&N cancer MDT are delivering the panel discussion for BAHNO Head & Neck this year. Lots of clinical dilemmas for us all to learn from. Audience participation essential! RadNetCRUKGlasgow NHS Greater Glasgow and Clyde #hncsm #BAHNO2024

🚨 From the lancet:
🔹Rand Phase III in NPC after primary Tx with >66Gy
🔹Normofractionated 60 Gy in 27 Fx vs HyperFx 65 Gy in 54 Fx Re-RT
🔹Strong OS benefit with HyperFx
🔹Grade V late Tox 24% with NormoFx, 7% with HFx
bit.ly/3J9Eohi #radonc #hncsm

Final result, happy and smiling patient. #brachytherapy #thisisbrachytherapy #radonc #cancer #hncsm

Slowly collecting more ENT friends 😀 #NRG2023 #hncsm

Grateful and humbled to have presented my residency paper on my home institution’s hypofractionated post-mastectomy radiotherapy #bcsm and my Radiation Medicine Program fellowship paper on outcomes on RT alone in cisplatin-ineligible #hncsm at #ASTRO2023
#radonc

Here it is! 🗞️ Presented today ESMO - Eur. Oncology #ESMO2023 and published concurrently in The Lancet Oncology Favorable survival with #neoadjuvant #immunotherapy in resectable #squamous #skin #cancer #cSCC cutaneous Squamous Cell Carcinoma (cSCC) Network #hncsm AHNS Regeneron MD Anderson Cancer Center

Thank you ⁦Nancy Lee⁩ for visiting us at ⁦VCU Massey Comprehensive Cancer Center⁩ ⁦VCU Radiation Oncology Residency⁩! It was great to hear about your inspiring work on personalization of therapy for head and neck cancer and new lines of exciting research for improvement of the therapeutic ratio for #hncsm !

Simposio de la FETTCC Fundación E. Tto. Tumores Cabeza y Cuello en #IFHNOS23 abordando los desafíos en el tratamiento del paciente frágil con #HNCSM no metastásico. SEOM SEORLCCC SEOR.es SECOMCyC

Congrats Alekh Thapa (he/him) 🏳️‍🌈 for leading this pan Scotland 🏴󠁧󠁢󠁳󠁣󠁴󠁿 collaboration 👏🏻
The UK divide - does having a pembro-chemo option in H&N cancer matter?
sciencedirect.com/science/articl…
#hncsm

#ASTRO23 Social Champion & #PatientAdvocate Julie McCrossin AM (She/Her) will join us in San Diego all the way from Australia to cover positive examples of RT innovations & research for patients & families. Learn more about Julie & other Social Champions here: astro.org/Meetings-and-E… #hncsm

How to do it better... an interesting session - building consensus on surgical margins in #hncsm AHNS

Great symposium this morning at #AHNS23 featuring Faden Lab research on HPV Deep Seek and fragmentomics for the early detection of an MRD state in HNSCC, potentially enabling earlier intervention and even screening. Because “all recurrences are, in reality, persistences.” #hncsm

Proud of Dr Pooja Karukonda for presenting our Financial Toxicity study of patients with HNCSM receiving radiation - Fumiko Ladd Chino, MD
Duke Radiation Oncology Radiation Oncology Institute
oncodaily.com/40923.html

#Cancer #OncoDaily #Oncology #RadiationOncology #Cancer Care

Great day to golf & fundraise for UW Department of Human Oncology head & neck program ⛳️ ☢️ #DreamTeam #hncsm

#AHNS23 Global Keynote by Dr. Pankaj Chaturvedi focused on healthcare delivery, research, and advocacy in low and middle income countries. It’s always amazing to hear about the successes and impacts of Tata Memorial Hospital #hncsm

1/N Finally out!! -- 30Gy for HPV+OPC in Journal of Clinical Oncology
– work by the Memorial Sloan Kettering Cancer Center Head and Neck team, led by Nancy Lee, Eric Sherman, and myself on using hypoxia imaging response to cut treatment 60% (70->30Gy)! #radonc #hncsm ascopubs.org/doi/10.1200/JC…